We noted you are experiencing viewing problems
-
Check with your IT department that JWPlatform, JWPlayer and Amazon AWS & CloudFront are not being blocked by your network. The relevant domains are *.jwplatform.com, *.jwpsrv.com, *.jwpcdn.com, jwpltx.com, jwpsrv.a.ssl.fastly.net, *.amazonaws.com and *.cloudfront.net. The relevant ports are 80 and 443.
-
Check the following talk links to see which ones work correctly:
Auto Mode
HTTP Progressive Download Send us your results from the above test links at access@hstalks.com and we will contact you with further advice on troubleshooting your viewing problems. -
No luck yet? More tips for troubleshooting viewing issues
-
Contact HST Support access@hstalks.com
-
Please review our troubleshooting guide for tips and advice on resolving your viewing problems.
-
For additional help, please don't hesitate to contact HST support access@hstalks.com
We hope you have enjoyed this limited-length demo
- Cancer/Oncology
-
2. Artificial intelligence in precision medicine
- Dr. Michael P. Menden
-
3. CAR-T and TCR-T cellular immunotherapies in oncology
- Prof. Sebastian Kobold
-
4. Precision cancer medicine: development and future
- Prof. Maurie Markman
-
5. Pediatric cancer testing
- Prof. Joshua Schiffman
- Neurology/Neuroscience
-
8. PANDAS: a potential link between group A streptococcal infections and neurological disorders
- Prof. P. Patrick Cleary
-
9. Characterizing barriers to care in migraine
- Prof. Dawn C. Buse
- Cardiovascular
-
10. Hypertrophic cardiomyopathy: therapies and treatments
- Prof. Srihari Naidu
- Respiratory Diseases
-
12. Predicting asthma exacerbations using machine learning models
- Dr. Nestor Molfino
- Immunology & Inflammation
-
13. Antiphospholipid syndrome and Lupus
- Prof. Graham Hughes
-
14. Opposition to vaccination: a transatlantic discussion
- Prof. Jonathan Temte
- Infectious Diseases/Microbiology
-
15. Combating the HIV epidemic
- Prof. William Blattner
-
16. Monkeypox: etiopathogenesis, prevention, and treatments
- Dr. Dennis Hruby
- Clinical Practice
-
18. Prescribing medications to children - a GP’s view
- Dr. Amanda Simmons
-
19. MAPS: the business of medical affairs
- Dr. Danie du Plessis
-
20. Kidney xenotransplantation
- Dr. Douglas J. Anderson
-
21. Epigenetic pharmaceuticals used in the clinic
- Dr. Thomas Paul
-
22. Elective caesarean sections from an evolutionary perspective
- Prof. Wenda Trevathan
Topics Covered
- Current treatment and containment strategies for HIV
- Current issues associated with prevention and containment
- International support and funding
- Economic and security implications
Biography
William Blattner graduated from Washington University in St. Louis, Missouri, USA with a Medical Doctor degree. His post graduate training was done at the University of Rochester and Cornell University. He completed his training in Medical Oncology at the National Cancer Institute, Bethesda Maryland. During his 22 year career at the National Cancer Institute he pioneered epidemiological research studies as a member of the team that co-discovered the HIV virus. These studies documented modes of transmission, disease associations and natural history. He co-founded with Professor Robert C. Gallo and Professor Robert Redfield the Institute of Human Virology at the University of Maryland, where his team pioneered international interventions that are foundational to global scale up of antiretroviral therapy in Africa, a cornerstone of the UNAIDS 90 90 90 strategy for ending the HIV epidemic. In 2016 he founded Salt Run Global Health and Research to support various domestic and international partners in public health and biomedical interventions.
Links
Series:
Categories:
Therapeutic Areas:
Talk Citation
Blattner, W. (2020, October 12). Combating the HIV epidemic [Audio file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved April 22, 2026, from https://doi.org/10.69645/GURY8123.Export Citation (RIS)
Publication History
- Published on October 12, 2020
Financial Disclosures
- Prof. William Blattner has not informed HSTalks of any commercial/financial relationship that it is appropriate to disclose.